Matsushima Soichiro, Maeda Kazuya, Inoue Katsuhisa, Ohta Kin-ya, Yuasa Hiroaki, Kondo Tsunenori, Nakayama Hideki, Horita Shigeru, Kusuhara Hiroyuki, Sugiyama Yuichi
Department of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.
Drug Metab Dispos. 2009 Mar;37(3):555-9. doi: 10.1124/dmd.108.023911. Epub 2008 Dec 12.
Cimetidine is known to cause drug-drug interactions (DDIs) with organic cations in the kidney, and a previous clinical study showed that coadministration of cimetidine or probenecid with fexofenadine (FEX) decreased its renal clearance. FEX was taken up into human kidney by human organic anion transporter (hOAT) 3 (SLC22A8), but the mechanism of its luminal efflux has not been clarified. The present study examined the molecular mechanism of these DDIs. Saturable uptake of FEX was observed in human kidney slices, with K(m) and V(max) values of 157+/-7 microM and 418+/-16 nmol/15 min/g kidney, respectively. Cimetidine only slightly inhibited its uptake even at 100 microM, far greater than its clinically relevant concentration, whereas 10 microM probenecid markedly inhibited its uptake. As candidate transporters for the luminal efflux of FEX, we focused on human multidrug and toxin extrusions MATE1 (SLC47A1) and MATE2-K (SLC47A2). Saturable uptake of FEX could be observed in human embryonic kidney 293 cells expressing human MATE1 (hMATE1), whereas hMATE2-K-specific uptake of FEX was too small to conduct its further kinetic analysis. The hMATE1-mediated uptake clearance of FEX was inhibited by cimetidine in a concentration-dependent manner, and it was decreased to 60% of the control value in the presence of 3 microM cimetidine. Taken together, our results suggest that the DDI of FEX with probenecid can be explained by the inhibition of renal uptake mediated by hOAT3, whereas the DDI with cimetidine is mainly caused by the inhibition of hMATE1-mediated efflux of FEX rather than the inhibition of its renal uptake process.
已知西咪替丁会在肾脏中与有机阳离子发生药物相互作用(DDIs),并且先前的一项临床研究表明,西咪替丁或丙磺舒与非索非那定(FEX)合用会降低其肾脏清除率。FEX通过人类有机阴离子转运体(hOAT)3(SLC22A8)被摄取到人类肾脏中,但其管腔外排机制尚未阐明。本研究探讨了这些DDIs的分子机制。在人肾切片中观察到FEX的饱和摄取,其K(m)和V(max)值分别为157±7 microM和418±16 nmol/15 min/g肾脏。即使在100 microM时,西咪替丁也仅轻微抑制其摄取,该浓度远高于其临床相关浓度,而10 microM丙磺舒则显著抑制其摄取。作为FEX管腔外排的候选转运体,我们关注了人类多药和毒素外排蛋白MATE1(SLC47A1)和MATE2-K(SLC47A2)。在表达人类MATE1(hMATE1)的人胚肾293细胞中可观察到FEX的饱和摄取,而hMATE2-K对FEX的特异性摄取太小,无法进行进一步的动力学分析。hMATE1介导的FEX摄取清除率被西咪替丁以浓度依赖的方式抑制,在存在3 microM西咪替丁的情况下,其降低至对照值的60%。综上所述,我们的结果表明,FEX与丙磺舒的DDI可通过抑制hOAT3介导的肾脏摄取来解释,而与西咪替丁的DDI主要是由抑制hMATE1介导的FEX外排而非抑制其肾脏摄取过程引起的。